Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Poult Sci ; 91(1): 66-73, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22184430

RESUMO

Polyphenolic compounds present in green tea, particularly catechins, are known to have strong anti-influenza activity. The goal of this study was to determine whether green tea by-products could function as an alternative to common antivirals in animals compared to original green tea. Inhibition of viral cytopathic effects ascertained by neutral red dye uptake was examined with 50% effective (virus-inhibitory) concentrations (EC50)determined. Against the H1N1 virus A/NWS/33, we found the anti-influenza activity of green tea by-products (EC50 = 6.36 µg/mL) to be equivalent to that of original green tea (EC50= 6.72 µg/mL). The anti-influenza activity of green tea by-products was further examined in mouse and chicken influenza infection models. In mice, oral administration of green tea by-products reduced viral titers in the lungs in the early phase of infection, but they could not protect these animals from disease and death. In contrast, therapeutic administration of green tea by-products via feed or water supplement resulted in a dose-dependent significant antiviral effect in chickens, with a dose of 10 g/kg of feed being the most effective (P < 0.001). We also demonstrated that unidentified hexane-soluble fractions of green tea by-products possessed strong anti-influenza activity, in addition to ethyl acetate-soluble fractions, including catechins. This study revealed green tea by-product extracts to be a promising novel antiviral resource for animals.


Assuntos
Antivirais/administração & dosagem , Camellia sinensis/química , Vírus da Influenza A Subtipo H1N1/efeitos dos fármacos , Vírus da Influenza A Subtipo H9N2/efeitos dos fármacos , Infecções por Orthomyxoviridae/veterinária , Extratos Vegetais/administração & dosagem , Administração Intranasal/veterinária , Administração Oral , Animais , Antivirais/química , Antivirais/farmacologia , Catequina/análogos & derivados , Catequina/química , Catequina/farmacologia , Linhagem Celular , Galinhas , Testes de Inibição da Hemaglutinação/veterinária , Camundongos , Camundongos Endogâmicos BALB C , Neuraminidase/antagonistas & inibidores , Vermelho Neutro/química , Infecções por Orthomyxoviridae/tratamento farmacológico , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Folhas de Planta/química , Reação em Cadeia da Polimerase Via Transcriptase Reversa/veterinária , Organismos Livres de Patógenos Específicos
2.
Poult Sci ; 90(5): 1020-2, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21489949

RESUMO

The frequent economic losses incurred with H9N2 low pathogenic avian influenza viruses (LPAI) infection have raised serious concerns for the poultry industry. A 1-dose regimen with inactivated H9N2 LPAI vaccine could not prevent vaccinated poultry from becoming infected and from shedding wild viruses. A study was conducted to determine whether a 2-dose regimen of inactivated H9N2 LPAI vaccine could enhance the immunologic response in chickens. Such gel-primed and mineral oil-boosted regimen has produced encouraging results associated with improved immune responses to an H9N2 LPAI. This strategy could be cost effective and helpful for preventing avian influenza virus in the poultry industry.


Assuntos
Galinhas , Vírus da Influenza A Subtipo H9N2/imunologia , Vacinas contra Influenza/imunologia , Influenza Aviária/prevenção & controle , Adjuvantes Imunológicos , Animais , Anticorpos Antivirais/sangue , Géis , Esquemas de Imunização , Imunização Secundária , Óleo Mineral , Organismos Livres de Patógenos Específicos , Vacinas de Produtos Inativados
3.
Eur J Cancer ; 32A(8): 1420-8, 1996 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8869109

RESUMO

The aim of this study was to determine the ability of the ginsenosides, extracts of Panax ginseng C.A. Meyer, to cause differentiation of F9 teratocarcinoma stem cells as a model system. F9 stem cells cultured in the presence of the ginsenosides together with dibutyryl cyclic AMP (dbcAMP) became parietal endoderm-like cells. Moreover, the expression of differentiation marker genes, such as laminin B1 and type IV collagen, was increased after treatment with the ginsenosides. Among the various purified ginsenosides, Rh1 and Rh2 were the most effective at causing differentiation of F9 cells. Since ginsenosides and glucocorticoid hormone have similar chemical structures, we examined the possibility of the involvement of a glucocorticoid receptor (GR) in the differentiation process induced by the ginsenosides. According to Southwestern blot analysis, a 94 kDa protein regarded as a GR was detected in F9 cells cultured in the medium containing the ginsenosides Rh1 or Rh2. In addition, F9 stem cells treated with the ginsenosides Rh1 or Rh2 and with RU486, a glucocorticoid antagonist with a high affinity for the GR, did not differentiate into endoderm cells morphologically, and the expression of laminin B1 gene was not induced in these cells. In a gel mobility shift assay, protein factors capable of binding to the glucocorticoid responsive element (GRE) specifically were detected in nuclear extracts of the ginsenoside-treated F9 cells. Moreover, overexpression of GR by cotransfection of GR expression vector and GRE-luciferase vector enhanced the transactivation activity of GRE promoter in the presence of ginsenosides Rh1 or Rh2 and was further augmented by dbcAMP. In addition, ginsenosides Rh1 and Rh2 bound to a GR assessed by whole-cell binding assay, even though the specific binding affinity was weaker compared to dexamethasone. Based on these data, we suggest that the ginsenosides Rh1 and Rh2 cause the differentiation of F9 cells and the effects of ginsenosides might be exerted via binding with a GR or its analogous nuclear receptor.


Assuntos
Células-Tronco Neoplásicas/efeitos dos fármacos , Panax , Plantas Medicinais , Saponinas/farmacologia , Teratocarcinoma/patologia , Animais , Diferenciação Celular/efeitos dos fármacos , Células-Tronco de Carcinoma Embrionário , Regulação Neoplásica da Expressão Gênica , Ginsenosídeos , Immunoblotting , Luciferases/metabolismo , Camundongos , Mifepristona/farmacologia , Receptores de Glucocorticoides/metabolismo , Saponinas/metabolismo , Ativação Transcricional , Células Tumorais Cultivadas/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA